Site-specific modification of anti-angiogenesis peptide HM-3 by polyethylene glycol molecular weight of 20 kDa

Journal of Biochemistry

Volumn 148, Issue 3, 2010, Pages 341-347

  Zhu, Beili ^a   Xu, Han Mei ^a   Zhao, Liming ^a   Huang, Xiaofeng ^a   Zhang, Fengguo ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

angiogenesis inhibition; HM 3; PEG20k HM 3; peptide; SC mPEG 20k

Indexed keywords

ANGIOGENESIS INHIBITOR; GLYCOL SUCCINIMIDYL CARBONATE; HM 3; MACROGOL; PACLITAXEL; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL MIGRATION; CONTROLLED STUDY; DRUG DEGRADATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG SYNTHESIS; ENDOTHELIUM CELL; FEMALE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR WEIGHT; MOUSE; NONHUMAN; RAT; TUMOR GROWTH;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL LINE, TUMOR; DRUG STABILITY; MELANOMA; MICE; NECROSIS; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDES; POLYETHYLENE GLYCOLS; RATS;

EID: 77956444508     PISSN: 0021924X     EISSN: 17562651     Source Type: Journal    
DOI: 10.1093/jb/mvq070     Document Type: Article

References (15)

1. OReilly, M.S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W.S., Flynn, E., Birkhead, J.R., Olsen, B.R., and Folkman, J. (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88, 277-285
2. Xu, H.-M., Zhang, G.Y., Ji, X.D., Cao, L., Shu, L., and Hua, Z.C. (2005) Expression of soluble, biologically active recombinant human endostatin in Escherichia coli. Protein Expr. Purif. 41, 252-258
3. Dhanabal, M., Volk, R., Ramchandran, R., Simons, M., and Sukhatme, V.P. (1999) Cloning, expression, and in vitro activity of human endostatin. Biochem. Biophys. Res. Commun. 258, 345-352
4. Folkman, J. (2006) Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action. Exp. Cell Res. 312, 594-607
5. Cattaneo, M.G., Pola, S., Francescato, P., Chillemi, F., and Vicentini, L.M. (2003) Human endostatin-derived synthetic peptides possess potent antiangiogenic properties in vitro and in vivo. Exp. Cell Res. 283, 230-236
6. Wickströ m, S.A., Alitalo, K., and Keski-Oja, J. (2004) An endostatin-derived peptide interacts with integrins and regulates actin cytoskeleton and migration of endothelial cells. J. Biol. Chem. 279, 20178-20185
7. Xu, H.-M., Yin, R-T., Chen, L.-S., Siraj, S., Huang, X., Wang, M., Fang, H., and Wang, Y. (2008) An RGDmodified endostatin-derived synthetic peptide shows antitumor activity in vivo. Bioconjug. Chem. 19, 1980-1986
8. Roberts, M.J., Bentley, M.D., and Harris, J.M. (2002) Chemistry for peptide and protein PEGylation. Adv. Drug Deliv. Rev. 54, 459-476
9. Caliceti, P. and Veronese, F.M. (2003) Pharmacokinetic and biodistribution properties of poly(ethylene glycol) protein conjugate. Adv. Drug Deliv. Rev. 55, 1261-1277
10. Kubetzko, S., Sarkar, C.A., and Plu ckthun, A. (2005) Protein PEGylation decreases observed target association rates via a dual blocking mechanism. Mol. Pharmacol. 68, 1439-1454
11. Tsubery, H., Mironchik, M., Fridkin, M., and Shechter, Y. (2004) Prolonging the action of protein and peptide drugs by a novel approach of reversible polyethylene glycol modification. J. Biol. Chem. 279, 38118-38124
12. Francesco, M.V. and Anna, M. (2008) The impact of PEGylation on biological therapies. Biodrugs 22, 315-329
13. Zhou, K., Zheng, X., Xu, H.-M., Zhang, J., Chen, Y., Xi, T., and Feng, T. (2009) Studies of polyethylene glycol modification of HM-3 polypeptides. Bioconjug. Chem. 20, 932-936
14. So, T., Ito, H., Tsujihata, Y., Hirata, M., Ueda, T., and Imoto, T. (1999) The molecular weight of monomethoxypolyethylene glycol(mPEG) to protein determines the immunotolerogenicity of mPEG proteins. Protein Eng. 12, 701-705
15. Roberts, M.J., Bentley, M.D., and Harris, J.M. (2002) Chemistry for peptide and protein PEGylation. Adv. Drug Deliv. Rev. 54, 459-476